Abstract
Down syndrome or trisomy 21 is the most common genetic disorder leading to mental retardation. One feature is impaired short- and long-term spatial memory, which has been linked to altered brain-derived neurotrophic factor (BDNF) levels. Mouse models of Down syndrome have been used to assess neurotrophin levels, and reduced BDNF has been demonstrated in brains of adult transgenic mice overexpressing Dyrk1a, a candidate gene for Down syndrome phenotypes. Given the link between DYRK1A overexpression and BDNF reduction in mice, we sought to assess a similar association in humans with Down syndrome. To determine the effect of DYRK1A overexpression on BDNF in the genomic context of both complete trisomy 21 and partial trisomy 21, we used lymphoblastoid cell lines from patients with complete aneuploidy of human chromosome 21 (three copies of DYRK1A) and from patients with partial aneuploidy having either two or three copies of DYRK1A. Decreased BDNF levels were found in lymphoblastoid cell lines from individuals with complete aneuploidy as well as those with partial aneuploidies conferring three DYRK1A alleles. In contrast, lymphoblastoid cell lines from individuals with partial trisomy 21 having only two DYRK1A copies displayed increased BDNF levels. A negative correlation was also detected between BDNF and DYRK1A levels in lymphoblastoid cell lines with complete aneuploidy of human chromosome 21. This finding indicates an upward regulatory role of DYRK1A expression on BDNF levels in lymphoblastoid cell lines and emphasizes the role of genetic variants associated with psychiatric disorders.
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Introduction
Down syndrome (DS), resulting from partial or complete trisomy for chromosome 21, is the most common genetic cause of mental retardation [1]. Individuals with DS exhibit multiple cognitive deficiencies, including impaired short- and long-term spatial memory [2]. Such cognitive deficiencies can be traced to abnormalities in the survival and functional maintenance of neurons, processes which are dependent upon neurotrophic factors. One of these growth factors, brain-derived neurotrophic factor (BDNF), regulates neuronal cell survival, differentiation, synaptic plasticity, and neurogenesis. BDNF has also been implicated in processes required for learning and memory, such as long-term potentiation [3]. Importantly, abnormal BDNF levels in the brain are associated with a wide range of neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease, and DS [4].
Mouse models of DS have been critical in developing our understanding of the expression of neurotrophins in conditions of cognitive impairment. For example, reduced levels of BDNF have been detected in the hippocampus and cortex of one commonly used mouse model of DS, Ts65Dn [5, 6]. Similarly, reduced BDNF expression has also been demonstrated at the mRNA level [7]. In another model, transgenic mice overexpressing Dyrk1a (orthologous to the gene found on human chromosome 21), BDNF protein expression is significantly reduced in adult brains [8]. Further, the altered expression of BDNF can be corrected by supplementing the drinking water of mice overexpressing DYRK1A with green tea polyphenol extract, which contains epigallocatechin gallate, an inhibitor of DYRK1A [9]. DYRK1A has been proposed as a candidate gene for DS phenotypes [10]. Transgenic mice overexpressing DYRK1A exhibit impaired spatial learning and memory, suggesting that DYRK1A overexpression in DS may contribute to mental retardation [11]. Genetic association tests across five major personality factors point to several SNPs within genes known for their functions in the brain and their effects on behavior and mental disorders. They notably include BDNF and DYRK1A, and these findings seem to reflect the phenotypic links between personality and psychiatric disorders [12]. We aimed to assess variability of DYRK1A and BDNF levels and their association in healthy individuals and DS patients to determine the link between these proteins and cognitive impairment.
Methods and Materials
Subjects and Sample Description
Blood samples were collected from participants into heparinized containers, and containers were immediately placed on ice until processed. Plasma was obtained by centrifugation of heparinized containers for 15 min at 2,000×g at 4 °C, then rapidly frozen and stored at −80 °C until analysis. Epstein–Barr virus-transformed lymphoblastoid cell lines (LCLs) were derived from B lymphocytes of healthy individuals and unrelated individuals with DS. LCLs are easy to grow and are widely used to study genotype–phenotype correlation [13]. Parents of patients from the Institut Jérôme Lejeune gave their informed consent, and the French biomedical ethics committee gave its approval for this study (Comité de Protection des Personnes dans la Recherche Biomédicale number 03025). Written informed consent was obtained from the participants or from their families by the cytogenetic service of the Hôpital Necker Enfants Malades and Hôpital Saint Etienne, the University of Geneva, the University of Adelaïde, the University of Nijmegen, and the University of Ghent. Cell lines from control individuals were also obtained with their written informed consent. LCLs were cultured in Opti-MEM with GlutaMax (Invitrogen, Cergy, France) supplemented with 5 % fetal bovine serum from a unique batch and 1 % penicillin and streptomycin mix (10,000 U/ml). Cell lines were grown at 37 °C in humidified incubators under 5 % CO2. For detailed structural Hsa21 aberration detection, high-resolution array CGH with NimbleGen HG18 chromosome 21 specific 385K arrays was used (B3752001-00-01; Roche NimbleGen Systems, Madison, WI, USA). The 385K average probe distance was 70 bases.
mRNA Expression Data
Total RNAs were obtained from LCLs using NucleoSpin RNA II kit in accordance with the manufacturer's protocol (Macherey Nagel, France). Using human pangenomic Illumina microarrays containing 48,701 probes, expression profiles for mRNAs from 43 LCLs from individuals with DS were obtained. Among the 48,701 probes on the microarrays, 11,224 probes corresponding to 9,758 genes displayed significant expression in LCLs. Results from three independent experiments (43 total samples from people with DS) were analyzed to identify differentially expressed genes. In a second experiment, Illumina beadchips were used to analyze 24 healthy individuals. Data were normalized using quantile normalization. Microarray data have been deposited in the GEO database with the number GSE34459.
Protein Preparation
Cells were harvested by centrifugation, washed in 5 ml PBS, centrifuged again, and stored at −80 °C. Cell lysates were obtained from 10 to 20 × 106 cell pellets treated with 300 μl of lysis buffer [Tris, 50 mM, pH8; NaCl, 150 mM; Igepal, 1 % (Sigma-Aldrich, France); SDS, 0.1 %] containing protease inhibitors (1 mM Pefabloc SC, 5 μg/ml E64, and 2.5 μg/ml Leupeptin). After centrifugation for 10 min at 15,000×g at 4 °C, the cell lysate was stored at −80 °C. The protein content of lysates was measured by Bio-Rad Protein Assay reagent (Bio-Rad).
BDNF Protein Analysis
BDNF levels were measured in either 100 μl of plasma (twice-diluted) or cell lysates from LCLs using the BDNF E-Max Immunoassay (ELISA E-Max, Promega, Madison, WI, USA). Plasma or cell lysates were incubated on a 96-well polystyrene ELISA plate previously coated with anti-BDNF monoclonal antibody. A standard curve was generated from serial dilutions of a human recombinant BDNF solution at 1 μg/ml. The captured neurotrophin was bound by a second specific antihuman BDNF polyclonal antibody, which was detected using a species-specific antibody conjugated to horseradish peroxidase (HRP). After removal of unbound conjugates, bound enzyme activity was assessed by chromogenic substrate for measurement at 450 nm by a microplate reader (Flex Station3, Molecular Device). All assays were performed in duplicate.
DYRK1A Protein Analysis
Protein preparation was blotted on a nitrocellulose membrane (ProtanR) using a slot blot apparatus (Proteigene, France). After transfer, membranes were saturated by incubation in 5 % w/v nonfat milk powder in Tris–saline buffer (1.5 mM Tris base, pH 8; 5 mM NaCl; 0.1 % Tween-20) and incubated overnight at 4 °C with antibodies against DYRK1A (1/250; Abnova Corporation, Tebu, France). Binding of the primary antibody was detected by incubation with HRP-conjugated secondary antibody using the Western Blotting Luminol Reagent (Santa Cruz Biotechnology, Tebu, France). Ponceau-S coloration was used as an internal control. Digitized images of the immunoblots obtained using an LAS-3000 imaging system (Fuji Photo Film Co., Ltd.) were used for densitometric measurements with an image analyzer (UnScan It software, Silk Scientific Inc.). All assays were performed in duplicate.
Statistical Analysis
Results are expressed as mean±SEM. Statistical analysis was performed with one-way ANOVA followed by Fisher post hoc test or by Student's unpaired t test using Statview software. Correlations were assessed with nonparametric Spearman's rank correlation test. Data were considered significant when p ≤ 0.05. A p value of 0.06–0.10 was considered to indicate a strong statistical tendency due to the small sample size.
Results
BDNF levels were determined in plasma from 24 individuals with DS (age 50 ± 10 years) and 14 healthy controls (age 50 ± 10 years). Plasma BDNF levels were significantly higher in participants with DS than in controls (Fig. 1), consistent with previous findings [14]. To determine the influence of DYRK1A expression on BDNF levels, we analyzed LCLs from individuals with complete aneuploidy for human chromosome 21 (Hsa21) (having three DYRK1A alleles; designated as “DS”) and LCLs from individuals with partial aneuploidy for Hsa21 with two (Aneu–2 DYRK1A) or three (Aneu–3 DYRK1A) DYRK1A alleles (Table 1). These cells were compared to LCLs from control individuals (having only two DYRK1A alleles). We first confirmed the overexpression of DYRK1A in LCLs from individuals with complete trisomy 21 and those with partial trisomy 21 having three DYRK1A alleles (Fig. 2a). Expression of DYRK1A was positively correlated with DYRK1A copy number (r = 0.367; p < 0.0161). Surprisingly, however, in contrast to BDNF expression in plasma from individuals with DS, BDNF expression in LCLs from individuals with DS was significantly decreased (Fig. 2b). A similar nonsignificant decrease in BDNF expression, due to the small number of samples, was found in LCLs from individuals with three DYRK1A alleles compared to controls. Conversely, BDNF expression was significantly higher in LCLs from individuals with two DYRK1A alleles compared to that in LCLs from individuals with three copies of DYRK1A (DS and Aneu–3 DYRK1A; Fig. 2b). Using human pangenomic Illumina microarrays, our attention was particularly drawn to the BDNF and DYRK1A gene expression. Among the 43 samples from people with DS, 16 were below the threshold significativity. We first verified the positive correlation between mRNA DYRK1A and DYRK1A protein levels (r = 0.451; p < 0.0153). Interestingly, a positive correlation between BDNF and DYRK1A gene expression was found in healthy individuals at the mRNA level (Fig. 3a) (r = 0.477; p < 0.0223) without correlation at the protein level (Fig. 3b). However, if we consider that there are two groups of healthy individuals, six controls have very low DYRK1A protein expression (below 0.6 AU) without correlation, but eight controls show a trend toward a positive correlation (r = 0.688; p < 0.0518) (Fig. 3b). On the contrary, a negative correlation was found not only at the mRNA level in individuals with DS (Fig. 3C) (r = −0.467; p < 0.0173) but also at the protein levels (Fig. 3d) (r = −0.589; p < 0.0275). Thus, DYRK1A expression affects mRNA and BDNF protein levels in LCLs from DS, but only BDNF mRNA expression in LCLs from healthy individuals.
Discussion
We have found that the association between trisomy 21 and BDNF levels is opposite for plasma and LCLs when individuals with DS are compared to healthy control individuals. BDNF is stored in human platelets; the concentration in serum is nearly identical to the concentration found in platelet lysates [15]. BDNF is also known to circulate in plasma, and the cellular sources are not clearly defined. We found a large variability in plasma BDNF levels in healthy individuals and those with DS. This could reflect the fact that many cellular sources, like vascular endothelial cells, smooth muscle cells, or activated macrophages or lymphocytes, may contribute to BDNF release in plasma [16–18]. BDNF is also a mediator of angiogenesis [19]. However, no difference was found in spontaneous BDNF release by circulating mononuclear cells [20]. If the endothelium contributes to the variability in BDNF release, it may also have a significant effect on variability of DYRK1A expression.
We demonstrate a negative correlation between BDNF and DYRK1A mRNA expression in LCLs from DS patients, but a positive correlation in LCLs from healthy individuals. Further, our results suggest that at least one locus on Hsa21 may act as a modifier of DYRK1A expression and one locus as a modifier of BDNF. BDNF expression is complicated by the existence of multiple promoters [21]. Additionally, CREB and NFAT, transcription factors that are substrates of DYRK1A [22, 23], have been shown to regulate expression of BDNF [24, 25]. There is no evidence to indicate that CREB and NFAT act synergistically or independently on BDNF expression or that they activate transcription from the same promoter [24, 25]. A previous study found that DSCR1 and DYRK1A act synergistically to prevent nuclear occupancy of NFATc transcription factors, leading to reduced NFATc activity [25]. Thus, reduced NFAT activity may be the link between DYRK1A overexpression and reduced BDNF levels in LCLs from people with DS. The observed variability in BDNF and DYRK1A expression might include a component due to the transformation of the lymphoblastoid cell lines. However, previous studies of murine models of DS [5, 8] and fetal samples [8, 9] suggest that the phenomenon in LCLs mimics that in brains.
The negative correlation found at the mRNA level in LCLs from DS patients was also found at the protein level. Importantly, a recent study demonstrated that Ts65Dn mice, a model of 120 genes in three copies, have lost correlations seen in control mice among levels of functionally related and neurologically important proteins [26]. Loss of normal correlation between BDNF and DYRK1A may underlie deficits in learning and memory. Personality traits are increasingly recognized as endophenotypes in genetic studies of mental disorders. An association has been demonstrated between BDNF polymorphism and anxiety- and depression-related personality traits [27]. In adults with DS, a high proportion of depression and/or anxiety disorders is frequently reported [28]. Given the role of BDNF in neuron maintenance and survival, this finding may explain the deleterious effects of DYRK1A overexpression on learning and memory in people with DS and emphasize the role of genetic variants associated with psychiatric disorders.
Abbreviations
- BDNF:
-
Brain-derived neurotrophic factor
- DS:
-
Down syndrome
- LCLs:
-
Lymphoblastoid cell lines
References
Antonarakis SE, Lyle R, Dermitzakis ET, Reymond A, Deutsch S (2004) Chromosome 21 and down syndrome: from genomics to pathophysiology. Nat Rev Genet 5:725–738
Brugge KL, Nichols SL, Salmon DP, Hill LR, Delis DC, Aaron L et al (1994) Cognitive impairment in adults with Down's syndrome: similarities to early cognitive changes in Alzheimer's disease. Neurology 44:232–238
Lebmann V (1998) Neurotrophin-dependent modulation of glutamatergic synaptic transmission in the mammalian CNS. Gen Pharmacol 31:667–674
Pezet S, Malcangio M (2004) Brain-derived neurotrophic factor as a drug target for CNS disorders. Expert Opin Ther Targets 8:391–399
Bimonte-Nelson HA, Hunter CL, Nelson ME, Granholm AC (2003) Frontal cortex BDNF levels correlate with working memory in an animal model of Down syndrome. Behav Brain Res 139:47–57
Fukuda Y, Berry TL, Nelson M, Hunter CL, Fukuhara K, Imai H et al (2010) Stimulated neuronal expression of brain-derived neurotrophic factor by neurotropin. Mol Cell Neurosci 45:226–233
Bianchi P, Ciani E, Guidi S, Trazzi S, Felice D, Grossi G et al (2010) Early pharmacotherapy restores neurogenesis and cognitive performance in the Ts65Dn mouse model for Down syndrome. J Neurosci 30:8769–8779
Toiber D, Azkona G, Ben-Ari S, Torán N, Soreq H, Dierssen M (2010) Engineering DYRK1A overdosage yields Down syndrome-characteristic cortical splicing aberrations. Neurobiol Dis 40:348–359
Guedj F, Sébrié C, Rivals I, Ledru A, Paly E, Bizot JC et al (2009) Green tea polyphenols rescue of brain defects induced by overexpression of DYRK1A. PLoS One 4:e4606
Dierssen M, de Lagrán MM (2006) DYRK1A (dual-specificity tyrosine-phosphorylated and -regulated kinase 1A:a gene with dosage effect during development and neurogenesis. Sci World J 6:1911–1922
Altafaj X, Dierssen M, Baamonde C, Martí E, Visa J, Guimerà J et al (2001) Neurodevelopmental delay, motor abnormalities and cognitive deficits in transgenic mice overexpressing Dyrk1A (minibrain), a murine model of Down's syndrome. Hum Mol Genet 10:1915–1923
Terracciano A, Sanna S, Uda M, Deiana B, Usala G, Busonero F et al (2010) Genome-wide association scan for five major dimensions of personality. Mol Psychiatry 15:647–656
Aït Yahya-Graison E, Aubert J, Dauphinot L, Rivals I, Prieur M, Golfier G et al (2007) Classification of human chromosome 21 gene-expression variations in Down syndrome: impact on disease phenotypes. Am J Hum Genet 81:475–491
Dogliotti G, Galliera E, Licastro F, Corsi MM (2010) Age-related changes in plasma levels of BDNF in Down syndrome patients. Immun Ageing 25:7–12
Fujimura H, Altar CA, Chen R, Nakamura T, Nakahashi T, Kambayashi J et al (2002) Brain-derived neurotrophic factor is stored in human platelets and released by agonist stimulation. Thromb Haemost 87:728–734
Donovan MJ, Miranda RC, Kraemer R, McCaffrey TA, Tessarollo L, Mahadeo D et al (1995) Neurotrophin and neurotrophin receptors in vascular smooth muscle cells. Regulation of expression in response to injury. Am J Pathol 147:309–324
Nakahashi T, Fujimura H, Altar CA, Li J, Kambayashi J, Tandon NN et al (2000) Vascular endothelial cells synthesize and secrete brain-derived neurotrophic factor. FEBS Lett 470:113–117
Kerschensteiner M, Gallmeier E, Behrens L, Leal VV, Misgeld T, Klinkert WE et al (1999) Activated human T cells, B cells, and monocytes produce brain-derived neurotrophic factor in vitro and in inflammatory brain lesions: a neuroprotective role of inflammation? J Exp Med 189:865–870
Kermani P, Hempstead B (2007) Brain-derived neurotrophic factor: a newly described mediator of angiogenesis. Trends Cardiovasc Med 17:140–143
Lommatzsch M, Zingler D, Schuhbaeck K, Schloetcke K, Zingler C, Schuff-Werner P et al (2005) The impact of age, weight and gender on BDNF levels in human platelets and plasma. Neurobiol Aging 26:115–123
Pruunsild P, Kazantseva A, Aid T, Palm K, Timmusk T (2007) Dissecting the human BDNF locus: bidirectional transcription, complex splicing, and multiple promoters. Genomics 90:397–406
Yang EJ, Ahn YS, Chung KC (2001) Protein kinase Dyrk1 activates cAMP response element-binding protein during neuronal differentiation in hippocampal progenitor cells. J Biol Chem 276:39819–39824
Arron JR, Winslow MM, Polleri A, Chang CP, Wu H, Gao X et al (2006) NFAT dysregulation by increased dosage of DSCR1 and DYRK1A on chromosome 21. Nature 441:595–600
Tao X, Finkbeiner S, Arnold DB, Shaywitz AJ, Greenberg ME (1998) Ca2+ influx regulates BDNF transcription by a CREB family transcription factor-dependent mechanism. Neuron 20:709–726
Groth RD, Mermelstein PG (2003) Brain-derived neurotrophic factor activation of NFAT (nuclear factor of activated T-cells)-dependent transcription: a role for the transcription factor NFATc4 in neurotrophin-mediated gene expression. J Neurosci 23:8125–8134
Ahmed MM, Sturgeon X, Ellison M, Davisson MT, Gardiner KJ (2012) Loss of correlations among proteins in brains of the Ts65Dn mouse model of Down syndrome. J Proteome Res 11:1251–1263
Lang UE, Hellweg R, Kalus P, Bajbouj M, Lenzen KP, Sander T et al (2005) Association of a functional BDNF polymorphism and anxiety-related personality traits. Psychopharmacology 180:95–99
Virji-Babul N, Eichmann A, Kisly D, Down J, Haslam RH (2007) Use of health care guidelines in patients with Down syndrome by family physicians across Canada. Paediatr Child Health 12:179–183
Acknowledgments
Measurement of BDNF level was performed on the FlexStation3 Facility of the Functional and Adaptative Biology (BFA) laboratory. This work was supported by a FP6 EU grant AnEUploidy, the Fondation Jérome Lejeune, and the Agence Nationale de la Recherche (MNP grant).
Financial Disclosures
None.
Author information
Authors and Affiliations
Corresponding author
Additional information
Jean-Maurice Delabar and Nathalie Janel share senior authorship.
Rights and permissions
About this article
Cite this article
Tlili, A., Hoischen, A., Ripoll, C. et al. BDNF and DYRK1A Are Variable and Inversely Correlated in Lymphoblastoid Cell Lines from Down Syndrome Patients. Mol Neurobiol 46, 297–303 (2012). https://doi.org/10.1007/s12035-012-8284-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12035-012-8284-7